Potassium channel activators in the management of ischaemic heart disease: a focus on nicorandil
Purcell, H.; Fox, K.
British Journal of Clinical Practice 47(3): 150-154
1993
ISSN/ISBN: 0007-0947 PMID: 8347442 Document Number: 415657
The treatment of angina pectoris continues to pose challenges. Novel new compounds are a rarity, but the potassium channel activators represent a new class of drugs with novel mechanisms of action. Nicorandil will be the first available potassium channel modulator for treatment of angina, and the following review assesses its clinical potential.
Document emailed within 1 workday
Related Documents
Longman, S.D.; Clapham, J.C.; Wilson, C.; Hamilton, T.C. 1988: Cromakalim, a potassium channel activator: a comparison of its cardiovascular haemodynamic profile and tissue specificity with those of pinacidil and nicorandil Journal of Cardiovascular Pharmacology 12(5): 535-542Zhang, S.; Sakai, K.; Hasuo, H.; Furuta, K.; Ureshino, H.; Shibata, O.; Sumikawa, K. 1999: Systemic and coronary hemodynamic effects of JTV-506, a novel potassium channel opener, in conscious dogs: comparison with cromakalim and nicorandil Research Communications in Molecular Pathology and Pharmacology 105(1-2): 115-127
Dupont, L.; Pirotte, B.; de Tullio, P.; Masereel, B.; Delarge, J. 1995: Potassium channel activators: comparative structural study of pinacidil, diazoxide and cromakalim Annales Pharmaceutiques Francaises 53(5): 201-208
Cleland, W.P. 1978: Surgical management of ischaemic heart disease British Journal of Clinical Practice 32(3): 67-72
Datey, K.K.; Kapadia, N.M.; Dalvi, C.P. 1974: Recent trends in the management of ischaemic heart disease Journal of the Association of Physicians of India 22(10): 759-765
Tulpule, T.H.; Shah, H.M.; Shah, S.J.; Haveliwala, H.K. 1971: Yogic exercises in the management of ischaemic heart disease Indian Heart Journal 23(4): 259-264
Grupe, A.; Schröter, K.H.; Ruppersberg, J.P.; Stocker, M.; Drewes, T.; Beckh, S.; Pongs, O. 1990: Cloning and expression of a human voltage-gated potassium channel. A novel member of the RCK potassium channel family EMBO Journal 9(6): 1749-1756
Bradic, J.; Petkovic, A.; Simonovic, N.; Radovanovic, M.; Jeremic, J.; Zivkovic, V.; Mitrovic, S.; Bolevich, S.; Jakovljevic, V.; Sretenovic, J.; Srejovic, I. 2019: Preconditioning with hyperbaric oxygen and calcium and potassium channel modulators in the rat heart Undersea and Hyperbaric Medicine: Journal of the Undersea and Hyperbaric Medical Society Inc 46(4): 483-494
Yarnell, J.W.; Limb, E.S.; Layzell, J.M.; Baker, I.A. 1992: Height: a risk marker for ischaemic heart disease: prospective results from the Caerphilly and Speedwell Heart Disease Studies European Heart Journal 13(12): 1602-1605
Wang, Z.-Q.; Jiang, X.-J.; Zhang, G.-Y.; Chen, M.; Tong, C.-F.; Zhang, D. 2016: Effects of ginseng-spikenard heart-nourishing capsule on inactivation of C-type Kv1.4 potassium channel Pakistan Journal of Pharmaceutical Sciences 29(5): 1513-1517
Kuz'ko, N.V. 1981: Use of anaerobic glycolysis activators in chronic ischemic heart disease Vrachebnoe Delo 3: 81-83
Ma, R.-Y.; Yang, Z.-Y.; Zhong, Q.-J. 2007: Effects of rapid atrial pacing on L-type calcium channel subunits and potassium channel Kv4.3 expressions in rabbits Zhonghua Xin Xue Guan Bing Za Zhi 35(12): 1111-1115
Golan, D.T.; Kursbaum, A. 1976: Anti-heart autoantibodies in ischaemic heart disease patients Clinical and Experimental Immunology 26(1): 86-90
1997: Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group Lancet 349(9049): 375-380
Malerba, M.; Radaeli, A.; Mancuso, S.; Polosa, R. 2010: The potential therapeutic role of potassium channel modulators in asthma and chronic obstructive pulmonary disease Journal of Biological Regulators and Homeostatic Agents 24(2): 123-130
Ludwig, J.; Terlau, H.; Wunder, F.; Brüggemann, A.; Pardo, L.A.; Marquardt, A.; Stühmer, W.; Pongs, O. 1994: Functional expression of a rat homologue of the voltage gated either á go-go potassium channel reveals differences in selectivity and activation kinetics between the Drosophila channel and its mammalian counterpart EMBO Journal 13(19): 4451-4458
Nony, P.; Boissel, J.P.; Girard, P.; Leizorovicz, A.; Lievre, M.; Chifflet, R. 1992: Relative efficacy of angiotensin converting enzyme inhibitors on mortality of patients with congestive heart failure: implications of randomized trials and role of the aetiology (ischaemic or non-ischaemic) of heart failure European Heart Journal 13(8): 1101-1108
Kaneko, T.; Hayashida, M.; Saito, Y.; Hikawa, Y.; Yasuda, K. 2000: The effect of prophylactic nicorandil infusion to reduce intraoperative myocardial ischemia during abdominal surgery in patients with risk factors of ischemic heart disease Masui. Japanese Journal of Anesthesiology 49(1): 54-59
Tiritilli, A.; Levy, P.; Haïat, R. 1995: Effects of nicorandil, a potassium agonist, on the human umbilical artery. Role of the vascular endothelium Archives des Maladies du Coeur et des Vaisseaux 88(8): 1095-1099
Sodi-Pollares, D. 1982: Theoretical effect in human heart disease of low-sodium high-potassium diet therapy on intracellular adsorbed sodium and potassium Physiological Chemistry and Physics 14(5): 439-443